Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 07, 2018 07:30 ET | Source: Avadel Pharmaceuticals plc

Avadel Pharmaceuticals Reports Second Quarter 2018 Financial Results

DUBLIN, Ireland, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ: AVDL), a company focused on providing innovative medicines for chronic urological, central nervous system, and...
July 17, 2018 07:33 ET | Source: Avadel Pharmaceuticals plc

Avadel Pharmaceuticals to Report Second Quarter 2018 Results

DUBLIN, Ireland, July 17, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq:AVDL), today announced it will report its second quarter 2018 financial results on Tuesday, August 7, 2018,...
May 31, 2018 16:01 ET | Source: Avadel Pharmaceuticals plc

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

DUBIN, Ireland, May 31, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq:AVDL), “Avadel” or the “Company,” today announced that management will present at two upcoming investor...
May 18, 2018 11:00 ET | Source: Avadel Pharmaceuticals plc

Avadel to Present Late-Breaker Data and Product Theater Forum at the 2018 American Urological Association Annual Meeting

Data demonstrates extended first uninterrupted sleep period in elderly patients Key opinion leaders to present “NOCTIVA™: Addressing a Nighttime Condition with Daytime Consequences” DUBLIN, Ireland,...
May 02, 2018 07:30 ET | Source: Avadel Pharmaceuticals plc

Avadel Pharmaceuticals Reports First Quarter 2018 Results

NOCTIVA™ launch underway across the U.S. FT 218 granted Orphan Drug Designation Generated revenue of $33.3 million DUBLIN, Ireland, May 02, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc...
May 01, 2018 09:43 ET | Source: Avadel Pharmaceuticals plc

Avadel Launches NOCTIVA™, the First and Only FDA-Approved Treatment for Nocturia Due to Nocturnal Polyuria

DUBLIN, Ireland, May 01, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq:AVDL) today announced the launch of NOCTIVA™ (desmopressin acetate), an emulsified microdose Nasal Spray. NOCTIVA...
April 30, 2018 16:01 ET | Source: Avadel Pharmaceuticals plc

Avadel Pharmaceuticals to Present at the Deutsche Bank 43rd Annual Health Care Conference

DUBLIN, Ireland, April 30, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq:AVDL), “Avadel” or “the Company,” today announced that Greg Divis, Chief Operating Officer, and Mike Kanan,...
April 24, 2018 07:30 ET | Source: Avadel Pharmaceuticals plc

Avadel Pharmaceuticals to Report First Quarter 2018 Results

DUBLIN, Ireland, April 24, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq:AVDL), today announced it will report its first quarter 2018 financial results on Wednesday, May 2, 2018,...
April 03, 2018 07:30 ET | Source: Avadel Pharmaceuticals plc

Avadel Pharmaceuticals Announces Acceptance of Late-Breaker Presentation for NOCTIVA™ at the 2018 American Urological Association

DUBLIN, Ireland, April 03, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq:AVDL), “Avadel” or the “Company,” today announced that new data from NOCTIVA’s pivotal Phase III clinical...
March 22, 2018 07:30 ET | Source: Avadel Pharmaceuticals plc

Avadel Pharmaceuticals Announces Promotion of Gregory J. Divis to Chief Operating Officer

DUBLIN, Ireland, March 22, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), “Avadel” or the “Company,” today announced the promotion of Gregory J. Divis to Executive Vice President...